Branding/Logomark minus Citation Combined Shape Icon/Bookmark-empty Icon/Copy Icon/Collection Icon/Close Copy 7 no author result Created with Sketch. Icon/Back Created with Sketch. Match!
Leona Plum-Mörschel
16Publications
5H-index
218Citations
Publications 16
Newest
Published on May 16, 2019in Clinical Pharmacokinectics 4.68
Inge B. Halberg1
Estimated H-index: 1
,
Karsten Lyby5
Estimated H-index: 5
+ 3 AuthorsEric Zijlstra10
Estimated H-index: 10
Background Oral insulin 338 is a novel tablet formulation of a long-acting basal insulin. This randomised, open-label, four-period crossover trial investigated the effect of timing of food intake on the single-dose pharmacokinetic properties of oral insulin 338.
Source Cite
Published on Apr 8, 2019in Diabetes, Obesity and Metabolism 6.13
Grégory Meiffren1
Estimated H-index: 1
,
Theresa Herbrand + 8 AuthorsOlivier Soula2
Estimated H-index: 2
Because of its physico-chemical properties, insulin glargine is usually not mixable with rapid insulins. BioChaperone BC147 is a polyanionic amphiphilic polymer, solubilizing insulin glargine at neutral pH, and thus enabling stable glargine formulation with fast-acting insulin lispro (BioChaperone glargine lispro co-formulation [BC Combo]). We investigated pharmacokinetic (PK) endpoints and postprandial glucose (PPG) control after administration of BC Combo (75% insulin glargine, 25% insulin lis...
Source Cite
Published on Mar 1, 2019in The Lancet Diabetes & Endocrinology 24.54
Inge B. Halberg1
Estimated H-index: 1
(Novo Nordisk),
Karsten Lyby5
Estimated H-index: 5
(Novo Nordisk)
+ 3 AuthorsLeona Plum-Mörschel5
Estimated H-index: 5
Summary Background Oral insulin 338 (I338) is a long-acting, basal insulin analogue formulated in a tablet with the absorption-enhancer sodium caprate. We investigated the efficacy and safety of I338 versus subcutaneous insulin glargine (IGlar) in patients with type 2 diabetes. Methods This was a phase 2, 8-week, randomised, double-blind, double-dummy, active-controlled, parallel trial completed at two research institutes in Germany. Insulin-naive adult patients with type 2 diabetes, inadequatel...
6 Citations Source Cite
Published on May 1, 2018in Diabetes, Obesity and Metabolism 6.13
Eric Zijlstra10
Estimated H-index: 10
,
Hans-Veit Coester4
Estimated H-index: 4
+ 6 AuthorsThomas Sparre14
Estimated H-index: 14
(Novo Nordisk)
1 Citations Source Cite
Published on May 1, 2018in Hormone and Metabolic Research 2.42
Thomas Forst40
Estimated H-index: 40
(University of Mainz),
Mohammed Khaled Alghdban1
Estimated H-index: 1
(University of Mainz)
+ 5 AuthorsLeona Plum-Mörschel5
Estimated H-index: 5
We investigated the effect of sequential treatment escalation with dapagliflozin and saxagliptin on beta cell function in patients with T2DM insufficiently controlled on metformin monotherapy during a hyperglycaemic clamp investigation. Twenty-six patients (19 males, age 63.5±7.0 years; duration of diabetes 8.8±4.7 years; HbA1c 63.9±15.8 mmol/mol; mean±SD) were enrolled in the study. During a first treatment period (TP1) all patients received 10 mg dapagliflozin for one month, followed by the ad...
1 Citations Source Cite
Published on Apr 1, 2017in Diabetes, Obesity and Metabolism 6.13
Thomas Forst40
Estimated H-index: 40
(University of Mainz),
Alexander Falk1
Estimated H-index: 1
+ 6 AuthorsLeona Plum-Mörschel5
Estimated H-index: 5
Aims The aim of the study was to investigate the effect of sequential treatment escalation with empagliflozin and linagliptin on laboratory markers of alpha- and beta cell function in patients with type 2 diabetes mellitus (T2DM) insufficiently controlled on metformin monotherapy. Methods Forty-four patients with T2DM received 25 mg empagliflozin for a duration of one month in an open-label fashion (treatment period (TP 1). Thereafter, patients were randomised to a double-blind add-on therapy wi...
6 Citations Source Cite
Published on Mar 1, 2017in Der Internist 0.43
Thomas Forst40
Estimated H-index: 40
(University of Mainz),
Leona Plum-Mörschel5
Estimated H-index: 5
,
Matthias M. Weber21
Estimated H-index: 21
(University of Mainz)
Bei Patienten mit einem Diabetes mellitus Typ 2 bestimmen kardiovaskulare Komplikationen masgeblich die Morbiditat und Mortalitat. In der Vergangenheit haben grose klinische Studien zum Einfluss einer blutzuckersenkenden Therapie auf kardiovaskulare Erkrankungen ein widerspruchliches Bild ergeben. Im Jahr 2008 haben die Zulassungsbehorden die Vorgaben fur den Beleg der kardiovaskularen Sicherheit neuer antidiabetischer Substanzen geandert. Seitdem wurden zahlreiche kardiovaskulare Endpunktstudie...
Source Cite
12